Literature DB >> 9886566

Characterization of the insulin-like growth factor axis in a human hepatoma cell line (PLC).

J G Scharf1, W Schmidt-Sandte, S A Pahernik, G Ramadori, T Braulke, H Hartmann.   

Abstract

The insulin-like growth factors (IGF-I and -II) are structurally related peptides participating in the regulation of metabolism, growth and cellular differentiation. In the present study, the human hepatoma cell line PLC was studied for the expression of individual components of the IGF axis. Northern blot analysis using IGF-I and -II coding cDNAs failed to detect IGF-I- or -II-specific transcripts in total RNA from PLC cells. Biosynthesis of type I and II IGF receptors was demonstrated by northern blotting and binding studies as well as cross-linking of the respective radiolabeled ligand. Both IGF-I and -II stimulated [3H]-thymidine incorporation dose-dependently. The mitogenic activity of exogenously added IGFs was reduced by the presence of IGF-binding proteins of 24, 30, 34, 41 and 45 kDa in supernatants of PLC cells identified as IGFBP-4, -1, -2 and -3, respectively, by [125I]IGF-I ligand-, immuno- and northern blotting. Biosynthesis of IGFBP-3 was stimulated dose-dependently by IGF-I and -II, while IGFBP-1, -2 and -4 were not affected. The increase of IGFBP-3 in response to IGF-I and -II was due to a stimulation of IGFBP-3 specific mRNA as well as to an inhibition of IGFBP-3 endocytosis. Proteolytic activity for rhIGFBP-3 was detected in media from PLC cells at acidic pH that was inhibited by the aspartyl protease inhibitor pepstatin A as well as after immunodepletion of cathepsin D from media of PLC cells. Thus, a role of cathepsin D for the regulation of IGFBP-3 bioavailability via endocytosis in acidic prelysosomal compartments was suggested. The susceptibility of PLC for IGF-I and -II was restricted by their ability to increase the abundance of inhibitory IGFBPs and to decrease the level of IGF-I receptor expression. The present data point to the IGF axis as a complex regulatory system that self limits the mitogenic activity of exogenous IGFs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9886566     DOI: 10.1093/carcin/19.12.2121

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  19 in total

1.  Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors.

Authors:  R Issa; E Williams; N Trim; T Kendall; M J Arthur; J Reichen; R C Benyon; J P Iredale
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

Review 2.  Targeting the insulin-like growth factor pathway in hepatocellular carcinoma.

Authors:  Mónica Enguita-Germán; Puri Fortes
Journal:  World J Hepatol       Date:  2014-10-27

3.  Insulin-like growth factor-1 mRNA isoforms and insulin-like growth factor-1 receptor mRNA expression in chronic hepatitis C.

Authors:  Aldona Kasprzak; Agnieszka Adamek; Wiesława Przybyszewska; Przemysław Pyda; Jacek Szmeja; Agnieszka Seraszek-Jaros; Agata Lanzafame; Anna Surdacka; Iwona Mozer-Lisewska; Maria Koczorowska
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

Review 4.  The IGF axis and hepatocarcinogenesis.

Authors:  J G Scharf; F Dombrowski; G Ramadori
Journal:  Mol Pathol       Date:  2001-06

5.  MicroRNA-497 regulates cell proliferation in hepatocellular carcinoma.

Authors:  Wen-Zhou Ding; Qing-Feng Ni; Ye-Ting Lu; Liang-Liang Kong; Jian-Jun Yu; Long-Wei Tan; Lian-Bao Kong
Journal:  Oncol Lett       Date:  2015-12-01       Impact factor: 2.967

6.  Serum IGFBP-3 is a more effective predictor than IGF-1 and IGF-2 for the development of hepatocellular carcinoma in patients with chronic HCV infection.

Authors:  Eiman Aleem; Ayman Elshayeb; Nihal Elhabachi; Amal Refaat Mansour; Ahmed Gowily; Asmaa Hela
Journal:  Oncol Lett       Date:  2011-12-30       Impact factor: 2.967

7.  miR-223 Deficiency Protects against Fas-Induced Hepatocyte Apoptosis and Liver Injury through Targeting Insulin-Like Growth Factor 1 Receptor.

Authors:  Ximena V Qadir; Weina Chen; Chang Han; Kyoungsub Song; Jinqiang Zhang; Tong Wu
Journal:  Am J Pathol       Date:  2015-12       Impact factor: 4.307

Review 8.  Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer.

Authors:  Michael Höpfner; Detlef Schuppan; Hans Scherübl
Journal:  World J Gastroenterol       Date:  2008-01-07       Impact factor: 5.742

9.  A replacement of the active-site aspartic acid residue 293 in mouse cathepsin D affects its intracellular stability, processing and transport in HEK-293 cells.

Authors:  Sanna Partanen; Stephan Storch; Hans-Gerhard Löffler; Andrej Hasilik; Jaana Tyynelä; Thomas Braulke
Journal:  Biochem J       Date:  2003-01-01       Impact factor: 3.857

Review 10.  Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease?

Authors:  Antonella Scalera; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.